written on 22.04.2014
Tags:
,

$16B deal for GlaxoSmithKline oncology meds turns Novartis into cancer heavyweight

TAGS: ,

Why would GlaxoSmithKline sell most of its cancer business to Novartis? In today's deal announcement, that particular sale stands up for questioning.
<div>
&nbsp;</div>

Latest Report